[Results of a clinical trial of a newly developped bronchospasmolytic agent (hexoprenalin, Ipradol)].
D000605:Amino Alcohols / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D006801:Humans; D009921:Metaproterenol / Q000494:pharmacology / Q000627:therapeutic use; D010276:Parasympatholytics / Q000009:adverse effects; D010627:Phenethylamines / Q000627:therapeutic use; D012138:Respiratory Therapy; D013997:Time Factors; D012122:Ventilators, Mechanical
D000605:Amino Alcohols; D001993:Bronchodilator Agents; D010276:Parasympatholytics; D010627:Phenethylamines; D009921:Metaproterenol
Ergebnisse der klinischen Prüfung eines neuentwickelten Bronchospasmolytikums (Hexoprenalin, Ipradol)